Hints and tips:
Related Special Reports
...“There is a compensation issue at AstraZeneca,” Jain, a top-20 shareholder, told the Financial Times....
...While acknowledging that AstraZeneca has “a global reach, is in a high-paying sector, with a particularly well-regarded CEO at the helm,” ISS said that it remained concern by “the scale of the increase”....
...In recommending that investors oppose the plans, ISS said it acknowledged that AstraZeneca, the UK’s second-largest public company by market value, has “a global reach, is in a high-paying sector, with a...
...The bill labels Shanghai-based WuXi AppTec “a biotechnology company of concern”, which is described as any entity posing a risk to the US by engaging in joint research with a foreign adversary’s military...
...drug breaks down into a carcinogen....
...It recently sold a large site in California to contract manufacturer Lonza for $1.2bn....
...As Emblaveo is a combination of two existing antibiotic treatments, aztreonam and avibactam, it would not qualify as a “priority” drug eligible for a voucher....
...or offer solutions for patients at a later stage.”...
...“This is a legal battle, but it’s a PR battle in many ways,” said Ana Santos Rutschman, a law professor at Villanova University in the US state of Pennsylvania, who is an expert in life sciences intellectual...
...A spokesperson for China’s Ministry of Foreign Affairs said: “China is a country ruled by law. All Chinese law enforcement and judicial activities are carried out based on facts and the law....
...“This is not a problem just for the heroin users. This is a problem for a wider population of people who use drugs, who might not think that they’re at risk of xylazine harm,” she added....
...“The whole system has a just-in-time principle and any rupture in that causes a downstream shortage,” says Rob Moss, a hospital pharmacy consultant in Utrecht, the Netherlands....
...Take a break from the news . . . and meet Tokyo’s top female sushi chefs who are expertly challenging convention in a male-dominated profession....
...AstraZeneca shareholders approved a potential £1.8mn pay rise for chief executive Pascal Soriot, despite a significant investor revolt against a pay increase advisers had called “excessive”....
...These price concessions increased from 20 instances per month before 2016 to a peak of 199 per month in late 2022....
...The success for Imfinzi, which is approved for other cancers, comes after a setback in a trial in November to expand its use for another terminal lung cancer....
...The company will increase its footprint at a Cambridge biomedical site and build a vaccine manufacturing site in Speke in Liverpool....
...Shareholders will vote later today on a plan to raise Soriot’s pay by £1.8mn to a maximum of £18.7mn in 2024....
...Novo Nordisk has struck a €1bn deal for a German biotech developing ribonucleic acid-based therapies to treat heart disease, as the Danish group invests the windfall from its best-selling diabetes and weight...
...The funds have been awarded by the British Business Bank, a state-owned lender.The money is part of the government’s ambition to encourage pension schemes to invest more in unlisted UK companies....
...Patients require a single treatment....
...The results from the research, which involved 156 people, were a “major breakthrough”, said Olivier Rascol, a Toulouse University Hospital professor and a co-author of the research with Prof Wassilios Meissner...
...Canadian biotech Fusion is a specialist in radioconjugates, a drug type that involves delivering a radioactive isotope directly to cancer cells through precise targeting, reducing the damaging side effects...
...Novo Nordisk has struck a €1bn deal for Cardior Pharmaceuticals, a German biotech company developing RNA-based therapies to treat heart disease, as it seeks to build expertise in diseases beyond diabetes...
International Edition